We believe that our lead product candidates have demonstrated, in clinical trials and/or in relevant preclinical models, potential advantages such as substantial increases in potency, duration of action and/or selectivity relative to existing medicines or potential medicines in late-stage clinical studies.
We have development programs in:


Theravance Key Programs   

KEY PROGRAMS DEVELOPMENT STATUS
BACTERIAL INFECTIONS:  
Telavancin: Nosocomial Pneumonia NDA Filed
RESPIRATORY:  
Horizon: Chronic Obstructive Pulmonary Disease Phase 3
Horizon: Asthma Phase 2 POC
Muscarinic Antagonist Beta2 Agonist (MABA) Phase 2 POC

In the table above:
  • Development Status indicates the most advanced stage of development that has been completed or is in process.
  • Phase 2 POC indicates that clinical safety testing and preliminary efficacy testing in a patient population has been successfully completed in at least one Phase 2 clinical study.
  • Phase 3 indicates evaluation of clinical efficacy and safety within an expanded patient population.
  • NDA Filed indicates that a new drug application has been submitted to and accepted for filing by the FDA.
©2010 Theravance, Inc. Theravance, the Theravance logo and Medicines That Make a Difference are registered trademarks of Theravance, Inc. Trademarks, trade names or service marks of other companies appearing on this website are the property of their respective owners. All rights reserved.

Terms of Use     Website Admin Contact     Theravance Contact     Site Map

By clicking on the link below, you will leave www.theravance.com.

www.VIBATIV.com